Dopamine transporter inhibitory and antiparkinsonian effect of common flowering quince extract

Pharmacology Biochemistry and Behavior

Volumn 90, Issue 3, 2008, Pages 363-371

  Zhao, Gang ^a,b   Jiang, Zhi Hua ^a,b   Zheng, Xiang wei ^a   Zang, Shao Yun ^a   Guo, Li He ^a,b  

^a Cell Star Bio Technologies Co Limited   (China)

^b INSTITUTE OF BIOCHEMISTRY AND CELL BIOLOGY   (China)

Author keywords

Antiparkinsonism; Common flowering quince; Dopamine; Parkinson's disease; Reuptake inhibitor; Transporter

Indexed keywords

1 METHYL 4 PHENYLPYRIDINIUM; 1,2,3,6 TETRAHYDRO 1 METHYL 4 PHENYLPYRIDINE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID CARRIER; 4 AMINOBUTYRIC ACID CARRIER 1; ANTIPARKINSON AGENT; DOPAMINE TRANSPORTER; OXIDOPAMINE; PLANT EXTRACT; QUINCE EXTRACT; SEROTONIN TRANSPORTER; TYROSINE 3 MONOOXYGENASE;

4 AMINOBUTYRIC ACID UPTAKE; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL VIABILITY; CHO CELL; CIRCLING BEHAVIOR; CONTROLLED STUDY; CYTOTOXICITY; DOPAMINE UPTAKE; DRUG EFFECT; DRUG INHIBITION; ENDURANCE; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; NONHUMAN; PARKINSONISM; PRIORITY JOURNAL; QUINCE; RAT; SEROTONIN UPTAKE; SUBSTANTIA NIGRA; SYNAPTOSOME;

1-METHYL-4-PHENYLPYRIDINIUM; ANIMALS; ANTIPARKINSON AGENTS; CELL LINE; CHO CELLS; CRICETINAE; CRICETULUS; DOPAMINE; DOPAMINE AGENTS; DOPAMINE PLASMA MEMBRANE TRANSPORT PROTEINS; DOPAMINE UPTAKE INHIBITORS; EXTRAPYRAMIDAL TRACTS; FRUIT; GABA PLASMA MEMBRANE TRANSPORT PROTEINS; HUMANS; MALE; MICE; MICE, INBRED C57BL; MUSCULOSKELETAL EQUILIBRIUM; NEOSTRIATUM; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; ORGANISMS, GENETICALLY MODIFIED; PLANT EXTRACTS; RATS; RATS, SPRAGUE-DAWLEY; ROSACEAE; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SYNAPTOSOMES;

CHAENOMELES SPECIOSA; CRICETULUS GRISEUS; CYDONIA OBLONGA; MUS; RATTUS;

EID: 44649156313     PISSN: 00913057     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pbb.2008.03.014     Document Type: Article

References (45)

1. Agnati L.F., Leo G., Vergoni A.V., Martinez E., Hockemeyer J., Lluis C., et al. Neuroprotective effect of L-DOPA co-administered with the adenosine A2A receptor agonist CGS 21680 in an animal model of Parkinson's disease. Brain Res Bull 64 (2004) 155-164
2. Ahlskog J.E., and Muenter M.D. Frequency of levodopa-related dyskinesias and motor fluctuations as estimated from the cumulative literature. Mov Disord 16 (2001) 448-458
3. An C.P., and Cheng W. Review on mechanisms and symptoms of depression in TCM (Traditional Chinese Medicine). Inf Tradit Chin Med 24 (2007) 12-14
4. Blum D., Torch S., Lambeng N., Nissou M., Benabid A.L., Sadoul R., et al. Molecular pathways involved in the neurotoxicity of 6-OHDA, dopamine and MPTP: contribution to the apoptotic theory in Parkinson's disease. Prog Neurobiol 65 (2001) 135-172
5. Chen Q., and Wei W. Effects and mechanisms of glucosides of Chaenomeles speciosa on collagen-induced arthritis in rats. Int Immunopharmacol 3 (2003) 593-608
6. Chiueh C.C., Andoh T., Lai A.R., Lai E., and Krishna G. Neuroprotective strategies in Parkinson's disease: protection against progressive nigral damage induced by free radicals. Neurotox Res 2 (2000) 293-310
7. Dai M., Wei W., Shen Y.X., and Zheng Y.Q. Glucosides of Chaenomeles speciosa remit rat adjuvant arthritis by inhibiting synoviocyte activities. Acta Pharmacol Sin 24 (2003) 1161-1166
8. Dawson T.M., and Dawson V.L. Molecular pathways of neurodegeneration in Parkinson's disease. Science 302 (2003) 819-822
9. Delwaide P.J., Martinelli P., and Schoenen J. Mazindol in the treatment of Parkinson's disease. Arch Neurol 40 (1983) 788-790
10. Eberhardt O., and Schulz J.B. Apoptotic mechanisms and antiapoptotic therapy in the MPTP model of Parkinson's disease. Toxicol Lett 139 (2003) 135-151
11. Goetz C.G., Tanner C.M., and Klawans H.L. Bupropion in Parkinson's disease. Neurology 34 (1984) 1092-1094
12. + incorporation into cerebellar granule cells. Brain Res Bull 56 (2001) 119-123
13. Hansard M.J., Smith L.A., Jackson M.J., Cheetham S.C., and Jenner P. Dopamine reuptake inhibition and failure to evoke dyskinesia in MPTP-treated primates. Eur J Pharmacol 451 (2002) 157-160
14. Hansard M.J., Smith L.A., Jackson M.J., Cheetham S.C., and Jenner P. Dopamine, but not norepinephrine or serotonin, reuptake inhibition reverses motor deficits in 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates. J Pharmacol Exp Ther 303 (2002) 952-958
15. He S.M., and Jiang J. Review on TCM treatment of migraine and tension-type headache. Chin Arch Tradit Chin Med 24 (2006) 1469-1471
16. Hersch S.M., Yi H., Heilman C.J., Edwards R.H., and Levey A.I. Subcellular locallization and molecular topology of dopamine transporter in the striatum and substantia nigra. J Comp Neurol 388 (1997) 211-227
17. Hurtig H.I. Problems with current pharmacologic treatment of Parkinson's disease. Exp Neurol 144 (1997) 10-16
18. Jenner P. Factors influencing the onset and persistence of dyskinesia in MPTP-treated primates. Ann Neurol 47 4 Suppl 1 (2000) S90-S104
19. Joyce J.N., Woolsey C., Ryoo H., Borwege S., and Hagner D. Low dose pramipexole is neuroprotective in the MPTP mouse model of Parkinson's disease, and downregulates the dopamine transporter via the D3 receptor. BMC Biol 2 (2004) 22
20. Kokoshka J.M., Metzger R.R., Wilkins D.G., Gibb J.W., Hanson G.R., and Fleckenstein A.E. Methamphetamine treatment rapidly inhibits serotonin, but not glutamate, transporters in rat brain. Brain Res 799 (1998) 78-83
21. Li C.Y., Ji X.H., Hui G.Z., Zhang J.G., Zhou W., Bu X.Y., et al. Effects of lobeline on dopamine uptake by plasma membrane dopamine transporter. Chin J Neurosurg Dis Res 6 (2007) 247-249
22. Liu Z., Wang Y., Zhao W., Ding J., Mei Z., Guo L., et al. Peptide derived from insulin with regulatory activity of dopamine transporter. Neuropharmacology 41 (2001) 464-471
23. McKinley E.T., Baranowski T.C., Blavo D.O., Cato C., Doan T.N., and Rubinstein A.L. Neuroprotection of MPTP-induced toxicity in zebrafish dopaminergic neurons. Brain Res Mol Brain Res 141 (2005) 128-137
24. Nelson N. The family of Na+/Cl- neurotransmitter transporters. J Neurochem 71 (1998) 1785-1803
25. Nutt J.G., Carter J.H., and Sexton G.J. The dopamine transporter: importance in Parkinson's disease. Ann Neurol 55 (2004) 766-773
26. Park D.M., Findley L.J., Hanks G., and Sandler M. Nomifensine: effect in Parkinsonian patients not receiving levodopa. J Neurol Neurosurg Psychiatry 44 (1981) 352-354
27. Park H.J., Lim S., Joo W.S., Yin C.S., Lee H.S., Lee H.J., et al. Acupuncture prevents 6-hydroxydopamine-induced neuronal death in the nigrostriatal dopaminergic system in the rat Parkinson's disease model. Exp Neurol 180 (2003) 93-98
28. Parkes J.D., Tarsy D., Marsden C.D., Bovill K.T., Phipps J.A., Rose P., et al. Amphetamines in the treatment of Parkinson's disease. J Neurol Neurosurg Psychiatry 38 (1975) 232-237
29. Pearce R.K., Jackson M., Britton D.R., Shiosaki K., Jenner P., and Marsden C.D. Actions of the D1 agonists A-77636 and A-86929 on locomotion and dyskinesia in MPTP-treated L-dopa-primed common marmosets. Psychopharmacology 142 (1999) 51-60
30. Pearce R.K., Smith L.A., Jackson M.J., Banerji T., Scheel-Kruger J., and Jenner P. The monoamine reuptake blocker brasofensine reverses akinesia without dyskinesia in MPTP-treated and levodopa-primed common marmosets. Mov Disord 17 (2002) 877-886
31. Pearce R.K.B. Dopamine D1 receptor agonists and dopamine reuptake blockers: new treatment stratagems for Parkinson's disease. Exp Opin Ther Patents 6 (1996) 949-953
32. Ravina B.M., Fagan S.C., Hart R.G., Hovinga C.A., Murphy D.D., Dawson T.M., et al. Neuroprotective agents for clinical trials in Parkinson's disease: a systematic assessment. Neurology 2 (2003) 1234-1240
33. Rosenzweig-Lipson S., Hesterberg P., and Bergman J. Observational studies of D1 and D2 agonists in squirrel monkeys. Psychopharmacology 116 (1994) 9-18
34. Rosner S., Giladi N., and Orr-Urtreger A. Advances in the genetics of Parkinson's disease. Acta Pharmacol Sin 29 (2008) 21-34
35. Rozas G., Lopez-Martin E., Guerra M.J., and Labandeira-Garcia J.L. The overall rod performance test in the MPTP-treated-mouse model of Parkinsonism. J Neurosci Methods 83 (1998) 165-175
36. Sulzer D. Multiple hit hypotheses for dopamine neuron loss in Parkinson's disease. Trends Neurosci 30 (2007) 244-250
37. Tanner C.M., and Ben-Shlomo Y. Epidemiology of Parkinson's disease. Adv Neurol 80 (1999) 153-159
38. Teychenne P.F., Park D.M., Findley L.J., Rose F.C., and Calne D.B. Nomifensine in parkinsonism. J Neurol Neurosurg Psychiatry 39 (1976) 1219-1221
39. Torres G.E., Gainetdinov R.R., and Caron M.G. Plasma membrane monoamine transporters: structure, regulation and function. Nat Rev Neurosci 4 (2003) 13-25
40. Wang L.Z. Therapy of apoplectic sequelae by six schemes. Henan Tradit Chin Med 26 (2006) 31-32
41. Watanabe Y., Himeda T., and Araki T. Mechanisms of MPTP toxicity and their implications for therapy of Parkinson's disease. Med Sci Monit 11 (2005) RA17-RA23
42. Wu H., Wei W., and Wu C.Y. Study on chemical composition and pharmacological activity of chaenomeles fruit. J Anhui Tradit Chin Med Coll 23 (2004) 62-64
43. Xu L.F., Chu W.J., Qing X.Y., Li S., Wang X.S., Qing G.W., et al. Protopine inhibits serotonin transporter and noradrenaline transporter and has the antidepressant-like effect in mice models. Neuropharmacology 50 (2006) 934-940
44. Xu M., Hu X.T., Cooper D.C., Moratalla R., Graybiel A.M., White F.J., et al. Elimination of cocaine-induced hyperactivity and dopamine-mediated neurophysiological effects in dopamine D1receptor mutant mice. Cell 79 (1994) 945-955
45. Yin K., Gao H.Y., Li X.N., and Wu L.J. Chemical constituents of Chaenomeles speciosa (Sweet) Nakai. J Shenyang Pharm Univ 23 (2006) 760-763